Cardiff Oncology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 |
| Selling, general & administrative | $14.2M | $12.5M | $13.0M | $13.2M | $11.8M |
| Research and development | $35.3M | $36.9M | $32.9M | $27.1M | $17.4M |
| Operating expenses | $49.6M | $49.3M | $45.9M | $40.3M | $29.2M |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | -$45.9M | -$45.4M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | -$28.3M |
| Balance Sheet | |||||
| Cash and equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M |
| Current assets | $60.1M | $95.1M | $77.4M | $111.3M | $146.1M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M |
| Current liabilities | $16.4M | $13.4M | $10.4M | $7.8M | $6.6M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M |
| Stockholders' equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M |
| Depreciation and amortization | $364,000 | $404,000 | $398,000 | $236,000 | $451,000 |
| Stock-based compensation | $5.7M | $4.8M | $4.5M | $4.3M | $3.2M |
| Capital expenditure | $44,000 | $80,000 | $582,000 | $1.0M | $205,000 |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M |
Shares outstanding 68.4M · Free float 89.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.